TY - JOUR AU - Crespo, J. PY - 2013 DA - 2013// TI - T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment JO - Curr Opin Immunol VL - 25 UR - https://doi.org/10.1016/j.coi.2012.12.003 DO - 10.1016/j.coi.2012.12.003 ID - Crespo2013 ER - TY - JOUR AU - Hayflick, L. AU - Moorhead, P. S. PY - 1961 DA - 1961// TI - The serial cultivation of human diploid cell strains JO - Exp Cell Res VL - 25 UR - https://doi.org/10.1016/0014-4827(61)90192-6 DO - 10.1016/0014-4827(61)90192-6 ID - Hayflick1961 ER - TY - JOUR AU - Wherry, E. J. AU - Kurachi, M. PY - 2015 DA - 2015// TI - Molecular and cellular insights into T cell exhaustion JO - Nat Rev Immunol VL - 15 UR - https://doi.org/10.1038/nri3862 DO - 10.1038/nri3862 ID - Wherry2015 ER - TY - JOUR AU - Angelosanto, J. M. PY - 2012 DA - 2012// TI - Progressive loss of memory T cell potential and commitment to exhaustion during chronic viral infection JO - J Virol VL - 86 UR - https://doi.org/10.1128/JVI.00889-12 DO - 10.1128/JVI.00889-12 ID - Angelosanto2012 ER - TY - JOUR AU - Brooks, D. G. AU - McGavern, D. B. AU - Oldstone, M. B. PY - 2006 DA - 2006// TI - Reprogramming of antiviral T cells prevents inactivation and restores T cell activity during persistent viral infection JO - J Clin Invest VL - 116 UR - https://doi.org/10.1172/JCI26856 DO - 10.1172/JCI26856 ID - Brooks2006 ER - TY - JOUR AU - Day, C. L. PY - 2006 DA - 2006// TI - PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression JO - Nature VL - 443 UR - https://doi.org/10.1038/nature05115 DO - 10.1038/nature05115 ID - Day2006 ER - TY - JOUR AU - Dyavar Shetty, R. PY - 2012 DA - 2012// TI - PD-1 blockade during chronic SIV infection reduces hyperimmune activation and microbial translocation in rhesus macaques JO - J Clin Invest VL - 122 UR - https://doi.org/10.1172/JCI60612 DO - 10.1172/JCI60612 ID - Dyavar Shetty2012 ER - TY - JOUR AU - Petrovas, C. PY - 2007 DA - 2007// TI - SIV-specific CD8+ T cells express high levels of PD1 and cytokines but have impaired proliferative capacity in acute and chronic SIVmac251 infection JO - Blood VL - 110 UR - https://doi.org/10.1182/blood-2007-01-069112 DO - 10.1182/blood-2007-01-069112 ID - Petrovas2007 ER - TY - JOUR AU - Yamamoto, T. PY - 2011 DA - 2011// TI - Surface expression patterns of negative regulatory molecules identify determinants of virus-specific CD8+ T-cell exhaustion in HIV infection JO - Blood VL - 117 UR - https://doi.org/10.1182/blood-2010-11-317297 DO - 10.1182/blood-2010-11-317297 ID - Yamamoto2011 ER - TY - JOUR AU - Gruener, N. H. PY - 2001 DA - 2001// TI - Sustained dysfunction of antiviral CD8+ T lymphocytes after infection with hepatitis C virus JO - J Virol VL - 75 UR - https://doi.org/10.1128/JVI.75.12.5550-5558.2001 DO - 10.1128/JVI.75.12.5550-5558.2001 ID - Gruener2001 ER - TY - JOUR AU - Radziewicz, H. PY - 2007 DA - 2007// TI - Liver-infiltrating lymphocytes in chronic human hepatitis C virus infection display an exhausted phenotype with high levels of PD-1 and low levels of CD127 expression JO - J Virol VL - 81 UR - https://doi.org/10.1128/JVI.02021-06 DO - 10.1128/JVI.02021-06 ID - Radziewicz2007 ER - TY - JOUR AU - Reignat, S. PY - 2002 DA - 2002// TI - Escaping high viral load exhaustion: CD8 cells with altered tetramer binding in chronic hepatitis B virus infection JO - J Exp Med VL - 195 UR - https://doi.org/10.1084/jem.20011723 DO - 10.1084/jem.20011723 ID - Reignat2002 ER - TY - JOUR AU - Urbani, S. PY - 2002 DA - 2002// TI - Virus-specific CD8+ lymphocytes share the same effector-memory phenotype but exhibit functional differences in acute hepatitis B and C JO - J Virol VL - 76 UR - https://doi.org/10.1128/JVI.76.24.12423-12434.2002 DO - 10.1128/JVI.76.24.12423-12434.2002 ID - Urbani2002 ER - TY - JOUR AU - Abdelbary, N. H. PY - 2011 DA - 2011// TI - Reduced Tim-3 expression on human T-lymphotropic virus type I (HTLV-I) Tax-specific cytotoxic T lymphocytes in HTLV-I infection JO - J Infect Dis VL - 203 UR - https://doi.org/10.1093/infdis/jiq153 DO - 10.1093/infdis/jiq153 ID - Abdelbary2011 ER - TY - JOUR AU - Ezinne, C. C. PY - 2014 DA - 2014// TI - HTLV-1 specific CD8+ T cell function augmented by blockade of 2B4/CD48 interaction in HTLV-1 infection JO - PLoS One VL - 9 UR - https://doi.org/10.1371/journal.pone.0087631 DO - 10.1371/journal.pone.0087631 ID - Ezinne2014 ER - TY - JOUR AU - Frebel, H. PY - 2012 DA - 2012// TI - Programmed death 1 protects from fatal circulatory failure during systemic virus infection of mice JO - J Exp Med VL - 209 UR - https://doi.org/10.1084/jem.20121015 DO - 10.1084/jem.20121015 ID - Frebel2012 ER - TY - JOUR AU - Nishimura, H. PY - 1999 DA - 1999// TI - Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor JO - Immunity VL - 11 UR - https://doi.org/10.1016/S1074-7613(00)80089-8 DO - 10.1016/S1074-7613(00)80089-8 ID - Nishimura1999 ER - TY - JOUR AU - McKinney, E. F. PY - 2015 DA - 2015// TI - T-cell exhaustion, co-stimulation and clinical outcome in autoimmunity and infection JO - Nature VL - 523 UR - https://doi.org/10.1038/nature14468 DO - 10.1038/nature14468 ID - McKinney2015 ER - TY - JOUR AU - Dong, H. PY - 2002 DA - 2002// TI - Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion JO - Nat Med VL - 8 ID - Dong2002 ER - TY - JOUR AU - Fourcade, J. PY - 2009 DA - 2009// TI - PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients JO - J Immunol VL - 182 UR - https://doi.org/10.4049/jimmunol.0803245 DO - 10.4049/jimmunol.0803245 ID - Fourcade2009 ER - TY - JOUR AU - Gassner, F. J. PY - 2014 DA - 2014// TI - Chemotherapy-induced augmentation of T cells expressing inhibitory receptors is reversed by treatment with lenalidomide in chronic lymphocytic leukemia JO - Haematologica VL - 99 UR - https://doi.org/10.3324/haematol.2013.098459 DO - 10.3324/haematol.2013.098459 ID - Gassner2014 ER - TY - JOUR AU - Lee, P. P. PY - 1999 DA - 1999// TI - Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients JO - Nat Med VL - 5 UR - https://doi.org/10.1038/9525 DO - 10.1038/9525 ID - Lee1999 ER - TY - JOUR AU - Baitsch, L. PY - 2011 DA - 2011// TI - Exhaustion of tumor-specific CD8(+) T cells in metastases from melanoma patients JO - J Clin Invest VL - 121 UR - https://doi.org/10.1172/JCI46102 DO - 10.1172/JCI46102 ID - Baitsch2011 ER - TY - JOUR AU - Gros, A. PY - 2014 DA - 2014// TI - PD-1 identifies the patient-specific CD8(+) tumor-reactive repertoire infiltrating human tumors JO - J Clin Invest VL - 124 UR - https://doi.org/10.1172/JCI73639 DO - 10.1172/JCI73639 ID - Gros2014 ER - TY - JOUR AU - Radoja, S. PY - 2001 DA - 2001// TI - CD8(+) tumor-infiltrating T cells are deficient in perforin-mediated cytolytic activity due to defective microtubule-organizing center mobilization and lytic granule exocytosis JO - J Immunol VL - 167 UR - https://doi.org/10.4049/jimmunol.167.9.5042 DO - 10.4049/jimmunol.167.9.5042 ID - Radoja2001 ER - TY - JOUR AU - Zenz, T. PY - 2013 DA - 2013// TI - Exhausting T cells in CLL JO - Blood VL - 121 UR - https://doi.org/10.1182/blood-2013-01-475939 DO - 10.1182/blood-2013-01-475939 ID - Zenz2013 ER - TY - JOUR AU - Im, S. J. PY - 2016 DA - 2016// TI - Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy JO - Nature VL - 537 UR - https://doi.org/10.1038/nature19330 DO - 10.1038/nature19330 ID - Im2016 ER - TY - JOUR AU - Utzschneider, D. T. PY - 2016 DA - 2016// TI - T Cell Factor 1-Expressing Memory-like CD8(+) T Cells Sustain the Immune Response to Chronic Viral Infections JO - Immunity VL - 45 UR - https://doi.org/10.1016/j.immuni.2016.07.021 DO - 10.1016/j.immuni.2016.07.021 ID - Utzschneider2016 ER - TY - JOUR AU - He, R. PY - 2016 DA - 2016// TI - Follicular CXCR5-expressing CD8+ T cells curtail chronic viral infection JO - Nature VL - 537 UR - https://doi.org/10.1038/nature19317 DO - 10.1038/nature19317 ID - He2016 ER - TY - JOUR AU - Freeman, G. J. PY - 1993 DA - 1993// TI - Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation JO - Science VL - 262 UR - https://doi.org/10.1126/science.7694363 DO - 10.1126/science.7694363 ID - Freeman1993 ER - TY - JOUR AU - Hathcock, K. S. PY - 1993 DA - 1993// TI - Identification of an alternative CTLA-4 ligand costimulatory for T cell activation JO - Science VL - 262 UR - https://doi.org/10.1126/science.7694361 DO - 10.1126/science.7694361 ID - Hathcock1993 ER - TY - JOUR AU - Azuma, M. PY - 1993 DA - 1993// TI - B70 antigen is a second ligand for CTLA-4 and CD28 JO - Nature VL - 366 UR - https://doi.org/10.1038/366076a0 DO - 10.1038/366076a0 ID - Azuma1993 ER - TY - JOUR AU - Rudd, C. E. AU - Taylor, A. AU - Schneider, H. PY - 2009 DA - 2009// TI - CD28 and CTLA-4 coreceptor expression and signal transduction JO - Immunol Rev VL - 229 UR - https://doi.org/10.1111/j.1600-065X.2009.00770.x DO - 10.1111/j.1600-065X.2009.00770.x ID - Rudd2009 ER - TY - JOUR AU - Qureshi, O. S. PY - 2011 DA - 2011// TI - Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4 JO - Science VL - 332 UR - https://doi.org/10.1126/science.1202947 DO - 10.1126/science.1202947 ID - Qureshi2011 ER - TY - JOUR AU - Alegre, M. L. PY - 1996 DA - 1996// TI - Regulation of surface and intracellular expression of CTLA4 on mouse T cells JO - J Immunol VL - 157 ID - Alegre1996 ER - TY - JOUR AU - Takahashi, T. PY - 2000 DA - 2000// TI - Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4 JO - J Exp Med VL - 192 UR - https://doi.org/10.1084/jem.192.2.303 DO - 10.1084/jem.192.2.303 ID - Takahashi2000 ER - TY - JOUR AU - Bour-Jordan, H. PY - 2011 DA - 2011// TI - Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/ B7 family JO - Immunol Rev VL - 241 UR - https://doi.org/10.1111/j.1600-065X.2011.01011.x DO - 10.1111/j.1600-065X.2011.01011.x ID - Bour-Jordan2011 ER - TY - JOUR AU - Tivol, E. A. PY - 1995 DA - 1995// TI - Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4 JO - Immunity VL - 3 UR - https://doi.org/10.1016/1074-7613(95)90125-6 DO - 10.1016/1074-7613(95)90125-6 ID - Tivol1995 ER - TY - JOUR AU - Waterhouse, P. PY - 1995 DA - 1995// TI - Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4 JO - Science VL - 270 UR - https://doi.org/10.1126/science.270.5238.985 DO - 10.1126/science.270.5238.985 ID - Waterhouse1995 ER - TY - JOUR AU - Wing, K. PY - 2008 DA - 2008// TI - CTLA-4 control over Foxp3+ regulatory T cell function JO - Science VL - 322 UR - https://doi.org/10.1126/science.1160062 DO - 10.1126/science.1160062 ID - Wing2008 ER - TY - JOUR AU - Peggs, K. S. PY - 2009 DA - 2009// TI - Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies JO - J Exp Med VL - 206 UR - https://doi.org/10.1084/jem.20082492 DO - 10.1084/jem.20082492 ID - Peggs2009 ER - TY - JOUR AU - Intlekofer, A. M. AU - Thompson, C. B. PY - 2013 DA - 2013// TI - At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy JO - J Leukoc Biol VL - 94 UR - https://doi.org/10.1189/jlb.1212621 DO - 10.1189/jlb.1212621 ID - Intlekofer2013 ER - TY - JOUR AU - Ishida, Y. PY - 1992 DA - 1992// TI - Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death JO - EMBO J VL - 11 ID - Ishida1992 ER - TY - JOUR AU - Freeman, G. J. PY - 2000 DA - 2000// TI - Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation JO - J Exp Med VL - 192 UR - https://doi.org/10.1084/jem.192.7.1027 DO - 10.1084/jem.192.7.1027 ID - Freeman2000 ER - TY - JOUR AU - Barber, D. L. PY - 2006 DA - 2006// TI - Restoring function in exhausted CD8 T cells during chronic viral infection JO - Nature VL - 439 UR - https://doi.org/10.1038/nature04444 DO - 10.1038/nature04444 ID - Barber2006 ER - TY - JOUR AU - Odorizzi, P. M. PY - 2015 DA - 2015// TI - Genetic absence of PD-1 promotes accumulation of terminally differentiated exhausted CD8+ T cells JO - J Exp Med VL - 212 UR - https://doi.org/10.1084/jem.20142237 DO - 10.1084/jem.20142237 ID - Odorizzi2015 ER - TY - JOUR AU - Yokosuka, T. PY - 2012 DA - 2012// TI - Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2 JO - J Exp Med VL - 209 UR - https://doi.org/10.1084/jem.20112741 DO - 10.1084/jem.20112741 ID - Yokosuka2012 ER - TY - JOUR AU - Parry, R. V. PY - 2005 DA - 2005// TI - CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms JO - Mol Cell Biol VL - 25 UR - https://doi.org/10.1128/MCB.25.21.9543-9553.2005 DO - 10.1128/MCB.25.21.9543-9553.2005 ID - Parry2005 ER - TY - JOUR AU - Patsoukis, N. PY - 2012 DA - 2012// TI - Selective effects of PD-1 on Akt and Ras pathways regulate molecular components of the cell cycle and inhibit T cell proliferation JO - Sci Signal VL - 5 UR - https://doi.org/10.1126/scisignal.2002796 DO - 10.1126/scisignal.2002796 ID - Patsoukis2012 ER - TY - JOUR AU - Park, H. J. PY - 2015 DA - 2015// TI - PD-1 upregulated on regulatory T cells during chronic virus infection enhances the suppression of CD8+ T cell immune response via the interaction with PD-L1 expressed on CD8+ T cells JO - J Immunol VL - 194 UR - https://doi.org/10.4049/jimmunol.1401936 DO - 10.4049/jimmunol.1401936 ID - Park2015 ER - TY - JOUR AU - Paley, M. A. PY - 2012 DA - 2012// TI - Progenitor and terminal subsets of CD8+ T cells cooperate to contain chronic viral infection JO - Science VL - 338 UR - https://doi.org/10.1126/science.1229620 DO - 10.1126/science.1229620 ID - Paley2012 ER - TY - JOUR AU - Blackburn, S. D. PY - 2008 DA - 2008// TI - Selective expansion of a subset of exhausted CD8 T cells by alphaPD-L1 blockade JO - Proc Natl Acad Sci U S A VL - 105 UR - https://doi.org/10.1073/pnas.0801497105 DO - 10.1073/pnas.0801497105 ID - Blackburn2008 ER - TY - JOUR AU - Yu, X. PY - 2009 DA - 2009// TI - The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells JO - Nat Immunol VL - 10 UR - https://doi.org/10.1038/ni.1674 DO - 10.1038/ni.1674 ID - Yu2009 ER - TY - JOUR AU - Stanietsky, N. PY - 2009 DA - 2009// TI - The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity JO - Proc Natl Acad Sci U S A VL - 106 UR - https://doi.org/10.1073/pnas.0903474106 DO - 10.1073/pnas.0903474106 ID - Stanietsky2009 ER - TY - JOUR AU - Mercier, I. AU - Lines, J. L. AU - Noelle, R. J. PY - 2015 DA - 2015// TI - Beyond CTLA-4 and PD-1, the Generation Z of Negative Checkpoint Regulators JO - Front Immunol VL - 6 UR - https://doi.org/10.3389/fimmu.2015.00418 DO - 10.3389/fimmu.2015.00418 ID - Mercier2015 ER - TY - JOUR AU - Godefroy, E. PY - 2015 DA - 2015// TI - TIGIT-positive circulating follicular helper T cells display robust B-cell help functions: potential role in sickle cell alloimmunization JO - Haematologica VL - 100 UR - https://doi.org/10.3324/haematol.2015.132738 DO - 10.3324/haematol.2015.132738 ID - Godefroy2015 ER - TY - JOUR AU - Li, M. PY - 2014 DA - 2014// TI - T-cell immunoglobulin and ITIM domain (TIGIT) receptor/poliovirus receptor (PVR) ligand engagement suppresses interferon-gamma production of natural killer cells via beta-arrestin 2-mediated negative signaling JO - J Biol Chem VL - 289 UR - https://doi.org/10.1074/jbc.M114.572420 DO - 10.1074/jbc.M114.572420 ID - Li2014 ER - TY - JOUR AU - Liu, S. PY - 2013 DA - 2013// TI - Recruitment of Grb2 and SHIP1 by the ITT-like motif of TIGIT suppresses granule polarization and cytotoxicity of NK cells JO - Cell Death Differ VL - 20 UR - https://doi.org/10.1038/cdd.2012.141 DO - 10.1038/cdd.2012.141 ID - Liu2013 ER - TY - JOUR AU - Levin, S. D. PY - 2011 DA - 2011// TI - Vstm3 is a member of the CD28 family and an important modulator of T-cell function JO - Eur J Immunol VL - 41 UR - https://doi.org/10.1002/eji.201041136 DO - 10.1002/eji.201041136 ID - Levin2011 ER - TY - JOUR AU - Carlsten, M. PY - 2007 DA - 2007// TI - DNAX accessory molecule-1 mediated recognition of freshly isolated ovarian carcinoma by resting natural killer cells JO - Cancer Res VL - 67 UR - https://doi.org/10.1158/0008-5472.CAN-06-2264 DO - 10.1158/0008-5472.CAN-06-2264 ID - Carlsten2007 ER - TY - JOUR AU - Masson, D. PY - 2001 DA - 2001// TI - Overexpression of the CD155 gene in human colorectal carcinoma JO - Gut VL - 49 UR - https://doi.org/10.1136/gut.49.2.236 DO - 10.1136/gut.49.2.236 ID - Masson2001 ER - TY - JOUR AU - Hirota, T. PY - 2005 DA - 2005// TI - Transcriptional activation of the mouse Necl-5/Tage4/PVR/CD155 gene by fibroblast growth factor or oncogenic Ras through the Raf-MEK-ERK-AP-1 pathway JO - Oncogene VL - 24 UR - https://doi.org/10.1038/sj.onc.1208409 DO - 10.1038/sj.onc.1208409 ID - Hirota2005 ER - TY - JOUR AU - Kamran, N. PY - 2013 DA - 2013// TI - Toll-like receptor ligands induce expression of the costimulatory molecule CD155 on antigen-presenting cells JO - PLoS One VL - 8 UR - https://doi.org/10.1371/journal.pone.0054406 DO - 10.1371/journal.pone.0054406 ID - Kamran2013 ER - TY - JOUR AU - Soriani, A. PY - 2009 DA - 2009// TI - ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype JO - Blood VL - 113 UR - https://doi.org/10.1182/blood-2008-08-173914 DO - 10.1182/blood-2008-08-173914 ID - Soriani2009 ER - TY - JOUR AU - Johnston, R. J. PY - 2014 DA - 2014// TI - The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function JO - Cancer Cell VL - 26 UR - https://doi.org/10.1016/j.ccell.2014.10.018 DO - 10.1016/j.ccell.2014.10.018 ID - Johnston2014 ER - TY - JOUR AU - Tahara-Hanaoka, S. PY - 2006 DA - 2006// TI - Tumor rejection by the poliovirus receptor family ligands of the DNAM-1 (CD226) receptor JO - Blood VL - 107 UR - https://doi.org/10.1182/blood-2005-04-1684 DO - 10.1182/blood-2005-04-1684 ID - Tahara-Hanaoka2006 ER - TY - JOUR AU - Welch, M. J. PY - 2012 DA - 2012// TI - CD8 T cell defect of TNF-alpha and IL-2 in DNAM-1 deficient mice delays clearance in vivo of a persistent virus infection JO - Virology VL - 429 UR - https://doi.org/10.1016/j.virol.2012.04.006 DO - 10.1016/j.virol.2012.04.006 ID - Welch2012 ER - TY - JOUR AU - Ramsbottom, K. M. PY - 2014 DA - 2014// TI - Cutting edge: DNAX accessory molecule 1-deficient CD8+ T cells display immunological synapse defects that impair antitumor immunity JO - J Immunol VL - 192 UR - https://doi.org/10.4049/jimmunol.1302197 DO - 10.4049/jimmunol.1302197 ID - Ramsbottom2014 ER - TY - JOUR AU - Zhang, T. PY - 2014 DA - 2014// TI - Increased expression of TIGIT on CD4+ T cells ameliorates immune-mediated bone marrow failure of aplastic anemia JO - J Cell Biochem VL - 115 ID - Zhang2014 ER - TY - JOUR AU - Zhang, Y. PY - 2013 DA - 2013// TI - Genome-wide DNA methylation analysis identifies hypomethylated genes regulated by FOXP3 in human regulatory T cells JO - Blood VL - 122 UR - https://doi.org/10.1182/blood-2013-02-481788 DO - 10.1182/blood-2013-02-481788 ID - Zhang2013 ER - TY - JOUR AU - Joller, N. PY - 2014 DA - 2014// TI - Treg cells expressing the coinhibitory molecule TIGIT selectively inhibit proinflammatory Th1 and Th17 cell responses JO - Immunity VL - 40 UR - https://doi.org/10.1016/j.immuni.2014.02.012 DO - 10.1016/j.immuni.2014.02.012 ID - Joller2014 ER - TY - JOUR AU - Mahnke, K. AU - Enk, A. H. PY - 2016 DA - 2016// TI - TIGIT-CD155 Interactions in Melanoma: A Novel Co-Inhibitory Pathway with Potential for Clinical Intervention JO - J Invest Dermatol VL - 136 UR - https://doi.org/10.1016/j.jid.2015.10.048 DO - 10.1016/j.jid.2015.10.048 ID - Mahnke2016 ER - TY - JOUR AU - Inozume, T. PY - 2016 DA - 2016// TI - Melanoma Cells Control Antimelanoma CTL Responses via Interaction between TIGIT and CD155 in the Effector Phase JO - J Invest Dermatol VL - 136 UR - https://doi.org/10.1038/JID.2015.404 DO - 10.1038/JID.2015.404 ID - Inozume2016 ER - TY - JOUR AU - Kurtulus, S. PY - 2015 DA - 2015// TI - TIGIT predominantly regulates the immune response via regulatory T cells JO - J Clin Invest VL - 125 UR - https://doi.org/10.1172/JCI81187 DO - 10.1172/JCI81187 ID - Kurtulus2015 ER - TY - JOUR AU - Huard, B. PY - 1995 DA - 1995// TI - CD4/major histocompatibility complex class II interaction analyzed with CD4- and lymphocyte activation gene-3 (LAG-3)-Ig fusion proteins JO - Eur J Immunol VL - 25 UR - https://doi.org/10.1002/eji.1830250949 DO - 10.1002/eji.1830250949 ID - Huard1995 ER - TY - JOUR AU - Triebel, F. PY - 1990 DA - 1990// TI - LAG-3, a novel lymphocyte activation gene closely related to CD4 JO - J Exp Med VL - 171 UR - https://doi.org/10.1084/jem.171.5.1393 DO - 10.1084/jem.171.5.1393 ID - Triebel1990 ER - TY - JOUR AU - Xu, F. PY - 2014 DA - 2014// TI - LSECtin expressed on melanoma cells promotes tumor progression by inhibiting antitumor T-cell responses JO - Cancer Res VL - 74 UR - https://doi.org/10.1158/0008-5472.CAN-13-2690 DO - 10.1158/0008-5472.CAN-13-2690 ID - Xu2014 ER - TY - JOUR AU - Baixeras, E. PY - 1992 DA - 1992// TI - Characterization of the lymphocyte activation gene 3-encoded protein. A new ligand for human leukocyte antigen class II antigens JO - J Exp Med VL - 176 UR - https://doi.org/10.1084/jem.176.2.327 DO - 10.1084/jem.176.2.327 ID - Baixeras1992 ER - TY - JOUR AU - Huang, C. T. PY - 2004 DA - 2004// TI - Role of LAG-3 in regulatory T cells JO - Immunity VL - 21 UR - https://doi.org/10.1016/j.immuni.2004.08.010 DO - 10.1016/j.immuni.2004.08.010 ID - Huang2004 ER - TY - JOUR AU - Kisielow, M. PY - 2005 DA - 2005// TI - Expression of lymphocyte activation gene 3 (LAG-3) on B cells is induced by T cells JO - Eur J Immunol VL - 35 UR - https://doi.org/10.1002/eji.200526090 DO - 10.1002/eji.200526090 ID - Kisielow2005 ER - TY - JOUR AU - Workman, C. J. PY - 2009 DA - 2009// TI - LAG-3 regulates plasmacytoid dendritic cell homeostasis JO - J Immunol VL - 182 UR - https://doi.org/10.4049/jimmunol.0800185 DO - 10.4049/jimmunol.0800185 ID - Workman2009 ER - TY - JOUR AU - Bae, J. PY - 2014 DA - 2014// TI - Trafficking of LAG-3 to the surface on activated T cells via its cytoplasmic domain and protein kinase C signaling JO - J Immunol VL - 193 UR - https://doi.org/10.4049/jimmunol.1401025 DO - 10.4049/jimmunol.1401025 ID - Bae2014 ER - TY - JOUR AU - Hannier, S. AU - Triebel, F. PY - 1999 DA - 1999// TI - The MHC class II ligand lymphocyte activation gene-3 is co-distributed with CD8 and CD3-TCR molecules after their engagement by mAb or peptide-MHC class I complexes JO - Int Immunol VL - 11 UR - https://doi.org/10.1093/intimm/11.11.1745 DO - 10.1093/intimm/11.11.1745 ID - Hannier1999 ER - TY - JOUR AU - Workman, C. J. AU - Dugger, K. J. AU - Vignali, D. A. PY - 2002 DA - 2002// TI - Cutting edge: molecular analysis of the negative regulatory function of lymphocyte activation gene-3 JO - J Immunol VL - 169 UR - https://doi.org/10.4049/jimmunol.169.10.5392 DO - 10.4049/jimmunol.169.10.5392 ID - Workman2002 ER - TY - JOUR AU - Macon-Lemaitre, L. AU - Triebel, F. PY - 2005 DA - 2005// TI - The negative regulatory function of the lymphocyte-activation gene-3 co-receptor (CD223) on human T cells JO - Immunology VL - 115 UR - https://doi.org/10.1111/j.1365-2567.2005.02145.x DO - 10.1111/j.1365-2567.2005.02145.x ID - Macon-Lemaitre2005 ER - TY - JOUR AU - Workman, C. J. PY - 2004 DA - 2004// TI - Lymphocyte activation gene-3 (CD223) regulates the size of the expanding T cell population following antigen activation in vivo JO - J Immunol VL - 172 UR - https://doi.org/10.4049/jimmunol.172.9.5450 DO - 10.4049/jimmunol.172.9.5450 ID - Workman2004 ER - TY - JOUR AU - Groux, H. PY - 1997 DA - 1997// TI - A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis JO - Nature VL - 389 UR - https://doi.org/10.1038/39614 DO - 10.1038/39614 ID - Groux1997 ER - TY - JOUR AU - Durham, N. M. PY - 2014 DA - 2014// TI - Lymphocyte Activation Gene 3 (LAG-3) modulates the ability of CD4 T-cells to be suppressed in vivo JO - PLoS One VL - 9 UR - https://doi.org/10.1371/journal.pone.0109080 DO - 10.1371/journal.pone.0109080 ID - Durham2014 ER - TY - JOUR AU - Blackburn, S. D. PY - 2009 DA - 2009// TI - Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection JO - Nat Immunol VL - 10 UR - https://doi.org/10.1038/ni.1679 DO - 10.1038/ni.1679 ID - Blackburn2009 ER - TY - JOUR AU - Matsuzaki, J. PY - 2010 DA - 2010// TI - Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer JO - Proc Natl Acad Sci U S A VL - 107 UR - https://doi.org/10.1073/pnas.1003345107 DO - 10.1073/pnas.1003345107 ID - Matsuzaki2010 ER - TY - JOUR AU - Woo, S. R. PY - 2012 DA - 2012// TI - Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape JO - Cancer Res VL - 72 UR - https://doi.org/10.1158/0008-5472.CAN-11-1620 DO - 10.1158/0008-5472.CAN-11-1620 ID - Woo2012 ER - TY - JOUR AU - McNerney, M. E. AU - Lee, K. M. AU - Kumar, V. PY - 2005 DA - 2005// TI - 2B4 (CD244) is a non-MHC binding receptor with multiple functions on natural killer cells and CD8+ T cells JO - Mol Immunol VL - 42 UR - https://doi.org/10.1016/j.molimm.2004.07.032 DO - 10.1016/j.molimm.2004.07.032 ID - McNerney2005 ER - TY - JOUR AU - Brown, M. H. PY - 1998 DA - 1998// TI - 2B4, the natural killer and T cell immunoglobulin superfamily surface protein, is a ligand for CD48 JO - J Exp Med VL - 188 UR - https://doi.org/10.1084/jem.188.11.2083 DO - 10.1084/jem.188.11.2083 ID - Brown1998 ER - TY - JOUR AU - Garni-Wagner, B. A. PY - 1993 DA - 1993// TI - A novel function-associated molecule related to non-MHC-restricted cytotoxicity mediated by activated natural killer cells and T cells JO - J Immunol VL - 151 ID - Garni-Wagner1993 ER - TY - JOUR AU - Nakajima, H. PY - 1999 DA - 1999// TI - Activating interactions in human NK cell recognition: the role of 2B4-CD48 JO - Eur J Immunol VL - 29 UR - https://doi.org/3.0.CO;2-Y DO - 3.0.CO;2-Y ID - Nakajima1999 ER - TY - JOUR AU - Muhammad, A. PY - 2009 DA - 2009// TI - Sequential cooperation of CD2 and CD48 in the buildup of the early TCR signalosome JO - J Immunol VL - 182 UR - https://doi.org/10.4049/jimmunol.0800691 DO - 10.4049/jimmunol.0800691 ID - Muhammad2009 ER - TY - JOUR AU - Chlewicki, L. K. PY - 2008 DA - 2008// TI - Molecular basis of the dual functions of 2B4 (CD244) JO - J Immunol VL - 180 UR - https://doi.org/10.4049/jimmunol.180.12.8159 DO - 10.4049/jimmunol.180.12.8159 ID - Chlewicki2008 ER - TY - JOUR AU - Eissmann, P. PY - 2005 DA - 2005// TI - Molecular basis for positive and negative signaling by the natural killer cell receptor 2B4 (CD244) JO - Blood VL - 105 UR - https://doi.org/10.1182/blood-2004-09-3796 DO - 10.1182/blood-2004-09-3796 ID - Eissmann2005 ER - TY - JOUR AU - Bloch-Queyrat, C. PY - 2005 DA - 2005// TI - Regulation of natural cytotoxicity by the adaptor SAP and the Src-related kinase Fyn JO - J Exp Med VL - 202 UR - https://doi.org/10.1084/jem.20050449 DO - 10.1084/jem.20050449 ID - Bloch-Queyrat2005 ER - TY - JOUR AU - Wherry, E. J. PY - 2007 DA - 2007// TI - Molecular signature of CD8+ T cell exhaustion during chronic viral infection JO - Immunity VL - 27 UR - https://doi.org/10.1016/j.immuni.2007.09.006 DO - 10.1016/j.immuni.2007.09.006 ID - Wherry2007 ER - TY - JOUR AU - Raziorrouh, B. PY - 2010 DA - 2010// TI - The immunoregulatory role of CD244 in chronic hepatitis B infection and its inhibitory potential on virus-specific CD8+ T-cell function JO - Hepatology VL - 52 UR - https://doi.org/10.1002/hep.23936 DO - 10.1002/hep.23936 ID - Raziorrouh2010 ER - TY - JOUR AU - Bengsch, B. PY - 2010 DA - 2010// TI - Coexpression of PD-1, 2B4, CD160 and KLRG1 on exhausted HCV-specific CD8+ T cells is linked to antigen recognition and T cell differentiation JO - PLoS Pathog VL - 6 UR - https://doi.org/10.1371/journal.ppat.1000947 DO - 10.1371/journal.ppat.1000947 ID - Bengsch2010 ER - TY - JOUR AU - Aldy, K. N. PY - 2011 DA - 2011// TI - 2B4+ CD8+ T cells play an inhibitory role against constrained HIV epitopes JO - Biochem Biophys Res Commun VL - 405 UR - https://doi.org/10.1016/j.bbrc.2011.01.062 DO - 10.1016/j.bbrc.2011.01.062 ID - Aldy2011 ER - TY - JOUR AU - Casado, J. G. PY - 2005 DA - 2005// TI - CD8 T cells expressing NK associated receptors are increased in melanoma patients and display an effector phenotype JO - Cancer Immunol Immunother VL - 54 UR - https://doi.org/10.1007/s00262-005-0682-5 DO - 10.1007/s00262-005-0682-5 ID - Casado2005 ER - TY - JOUR AU - Enose-Akahata, Y. PY - 2009 DA - 2009// TI - High expression of CD244 and SAP regulated CD8 T cell responses of patients with HTLV-I associated neurologic disease JO - PLoS Pathog VL - 5 UR - https://doi.org/10.1371/journal.ppat.1000682 DO - 10.1371/journal.ppat.1000682 ID - Enose-Akahata2009 ER - TY - JOUR AU - West, E. E. PY - 2011 DA - 2011// TI - Tight regulation of memory CD8(+) T cells limits their effectiveness during sustained high viral load JO - Immunity VL - 35 UR - https://doi.org/10.1016/j.immuni.2011.05.017 DO - 10.1016/j.immuni.2011.05.017 ID - West2011 ER - TY - JOUR AU - Han, P. PY - 2004 DA - 2004// TI - An inhibitory Ig superfamily protein expressed by lymphocytes and APCs is also an early marker of thymocyte positive selection JO - J Immunol VL - 172 UR - https://doi.org/10.4049/jimmunol.172.10.5931 DO - 10.4049/jimmunol.172.10.5931 ID - Han2004 ER - TY - JOUR AU - Watanabe, N. PY - 2003 DA - 2003// TI - BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1 JO - Nat Immunol VL - 4 UR - https://doi.org/10.1038/ni944 DO - 10.1038/ni944 ID - Watanabe2003 ER - TY - JOUR AU - Sedy, J. R. PY - 2005 DA - 2005// TI - B and T lymphocyte attenuator regulates T cell activation through interaction with herpesvirus entry mediator JO - Nat Immunol VL - 6 UR - https://doi.org/10.1038/ni1144 DO - 10.1038/ni1144 ID - Sedy2005 ER - TY - JOUR AU - Cai, G. PY - 2008 DA - 2008// TI - CD160 inhibits activation of human CD4+ T cells through interaction with herpesvirus entry mediator JO - Nat Immunol VL - 9 UR - https://doi.org/10.1038/ni1554 DO - 10.1038/ni1554 ID - Cai2008 ER - TY - JOUR AU - Gonzalez, L. C. PY - 2005 DA - 2005// TI - A coreceptor interaction between the CD28 and TNF receptor family members B and T lymphocyte attenuator and herpesvirus entry mediator JO - Proc Natl Acad Sci U S A VL - 102 UR - https://doi.org/10.1073/pnas.0409071102 DO - 10.1073/pnas.0409071102 ID - Gonzalez2005 ER - TY - JOUR AU - Oya, Y. PY - 2008 DA - 2008// TI - Development of autoimmune hepatitis-like disease and production of autoantibodies to nuclear antigens in mice lacking B and T lymphocyte attenuator JO - Arthritis Rheum VL - 58 UR - https://doi.org/10.1002/art.23674 DO - 10.1002/art.23674 ID - Oya2008 ER - TY - JOUR AU - Albring, J. C. PY - 2010 DA - 2010// TI - Targeting of B and T lymphocyte associated (BTLA) prevents graft-versus-host disease without global immunosuppression JO - J Exp Med VL - 207 UR - https://doi.org/10.1084/jem.20102017 DO - 10.1084/jem.20102017 ID - Albring2010 ER - TY - JOUR AU - Uchiyama, M. PY - 2014 DA - 2014// TI - An agonistic anti-BTLA mAb (3C10) induced generation of IL-10-dependent regulatory CD4+ T cells and prolongation of murine cardiac allograft JO - Transplantation VL - 97 UR - https://doi.org/10.1097/01.TP.0000438204.96723.8b DO - 10.1097/01.TP.0000438204.96723.8b ID - Uchiyama2014 ER - TY - JOUR AU - Deppong, C. PY - 2008 DA - 2008// TI - B and T lymphocyte attenuator regulates T cell survival in the lung JO - J Immunol VL - 181 UR - https://doi.org/10.4049/jimmunol.181.5.2973 DO - 10.4049/jimmunol.181.5.2973 ID - Deppong2008 ER - TY - JOUR AU - Steinberg, M. W. PY - 2008 DA - 2008// TI - A crucial role for HVEM and BTLA in preventing intestinal inflammation JO - J Exp Med VL - 205 UR - https://doi.org/10.1084/jem.20071160 DO - 10.1084/jem.20071160 ID - Steinberg2008 ER - TY - JOUR AU - Flynn, R. PY - 2013 DA - 2013// TI - CD8 T cell memory to a viral pathogen requires trans cosignaling between HVEM and BTLA JO - PLoS One VL - 8 UR - https://doi.org/10.1371/journal.pone.0077991 DO - 10.1371/journal.pone.0077991 ID - Flynn2013 ER - TY - JOUR AU - Pasero, C. PY - 2012 DA - 2012// TI - The HVEM network: new directions in targeting novel costimulatory/co-inhibitory molecules for cancer therapy JO - Curr Opin Pharmacol VL - 12 UR - https://doi.org/10.1016/j.coph.2012.03.001 DO - 10.1016/j.coph.2012.03.001 ID - Pasero2012 ER - TY - JOUR AU - M'Hidi, H. PY - 2009 DA - 2009// TI - High expression of the inhibitory receptor BTLA in T-follicular helper cells and in B-cell small lymphocytic lymphoma/chronic lymphocytic leukemia JO - Am J Clin Pathol VL - 132 UR - https://doi.org/10.1309/AJCPPHKGYYGGL39C DO - 10.1309/AJCPPHKGYYGGL39C ID - M'Hidi2009 ER - TY - JOUR AU - Derre, L. PY - 2010 DA - 2010// TI - BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination JO - J Clin Invest VL - 120 UR - https://doi.org/10.1172/JCI40070 DO - 10.1172/JCI40070 ID - Derre2010 ER - TY - JOUR AU - Fourcade, J. PY - 2012 DA - 2012// TI - CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1 JO - Cancer Res VL - 72 UR - https://doi.org/10.1158/0008-5472.CAN-11-2637 DO - 10.1158/0008-5472.CAN-11-2637 ID - Fourcade2012 ER - TY - JOUR AU - Thommen, D. S. PY - 2015 DA - 2015// TI - Progression of Lung Cancer Is Associated with Increased Dysfunction of T Cells Defined by Coexpression of Multiple Inhibitory Receptors JO - Cancer Immunol Res VL - 3 UR - https://doi.org/10.1158/2326-6066.CIR-15-0097 DO - 10.1158/2326-6066.CIR-15-0097 ID - Thommen2015 ER - TY - JOUR AU - Lou, Y. PY - 2016 DA - 2016// TI - Epithelial-Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma JO - Clin Cancer Res VL - 22 UR - https://doi.org/10.1158/1078-0432.CCR-15-1434 DO - 10.1158/1078-0432.CCR-15-1434 ID - Lou2016 ER - TY - JOUR AU - Lasaro, M. O. PY - 2011 DA - 2011// TI - Active immunotherapy combined with blockade of a coinhibitory pathway achieves regression of large tumor masses in cancer-prone mice JO - Mol Ther VL - 19 UR - https://doi.org/10.1038/mt.2011.88 DO - 10.1038/mt.2011.88 ID - Lasaro2011 ER - TY - JOUR AU - Hobo, W. PY - 2012 DA - 2012// TI - B and T lymphocyte attenuator mediates inhibition of tumor-reactive CD8+ T cells in patients after allogeneic stem cell transplantation JO - J Immunol VL - 189 UR - https://doi.org/10.4049/jimmunol.1102807 DO - 10.4049/jimmunol.1102807 ID - Hobo2012 ER - TY - JOUR AU - Anderson, A. C. PY - 2010 DA - 2010// TI - T-bet, a Th1 transcription factor regulates the expression of Tim-3 JO - Eur J Immunol VL - 40 UR - https://doi.org/10.1002/eji.200939842 DO - 10.1002/eji.200939842 ID - Anderson2010 ER - TY - JOUR AU - Monney, L. PY - 2002 DA - 2002// TI - Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease JO - Nature VL - 415 UR - https://doi.org/10.1038/415536a DO - 10.1038/415536a ID - Monney2002 ER - TY - JOUR AU - Asakura, H. PY - 2002 DA - 2002// TI - Selective eosinophil adhesion to fibroblast via IFN-gamma-induced galectin-9 JO - J Immunol VL - 169 UR - https://doi.org/10.4049/jimmunol.169.10.5912 DO - 10.4049/jimmunol.169.10.5912 ID - Asakura2002 ER - TY - JOUR AU - Lee, J. PY - 2011 DA - 2011// TI - Phosphotyrosine-dependent coupling of Tim-3 to T-cell receptor signaling pathways JO - Mol Cell Biol VL - 31 UR - https://doi.org/10.1128/MCB.05297-11 DO - 10.1128/MCB.05297-11 ID - Lee2011 ER - TY - JOUR AU - Zhu, C. PY - 2005 DA - 2005// TI - The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity JO - Nat Immunol VL - 6 UR - https://doi.org/10.1038/ni1271 DO - 10.1038/ni1271 ID - Zhu2005 ER - TY - JOUR AU - Sehrawat, S. PY - 2010 DA - 2010// TI - Galectin-9/TIM-3 interaction regulates virus-specific primary and memory CD8 T cell response JO - PLoS Pathog VL - 6 UR - https://doi.org/10.1371/journal.ppat.1000882 DO - 10.1371/journal.ppat.1000882 ID - Sehrawat2010 ER - TY - JOUR AU - Huang, Y. H. PY - 2015 DA - 2015// TI - CEACAM1 regulates TIM-3-mediated tolerance and exhaustion JO - Nature VL - 517 UR - https://doi.org/10.1038/nature13848 DO - 10.1038/nature13848 ID - Huang2015 ER - TY - JOUR AU - Chiba, S. PY - 2012 DA - 2012// TI - Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1 JO - Nat Immunol VL - 13 UR - https://doi.org/10.1038/ni.2376 DO - 10.1038/ni.2376 ID - Chiba2012 ER - TY - JOUR AU - Freeman, G. J. PY - 2010 DA - 2010// TI - TIM genes: a family of cell surface phosphatidylserine receptors that regulate innate and adaptive immunity JO - Immunol Rev VL - 235 UR - https://doi.org/10.1111/j.0105-2896.2010.00903.x DO - 10.1111/j.0105-2896.2010.00903.x ID - Freeman2010 ER - TY - JOUR AU - Kearley, J. AU - McMillan, S. J. AU - Lloyd, C. M. PY - 2007 DA - 2007// TI - Th2-driven, allergen-induced airway inflammation is reduced after treatment with anti-Tim-3 antibody in vivo JO - J Exp Med VL - 204 UR - https://doi.org/10.1084/jem.20062093 DO - 10.1084/jem.20062093 ID - Kearley2007 ER - TY - JOUR AU - Lee, S. Y. AU - Goverman, J. M. PY - 2013 DA - 2013// TI - The influence of T cell Ig mucin-3 signaling on central nervous system autoimmune disease is determined by the effector function of the pathogenic T cells JO - J Immunol VL - 190 UR - https://doi.org/10.4049/jimmunol.1300083 DO - 10.4049/jimmunol.1300083 ID - Lee2013 ER - TY - JOUR AU - Veenstra, R. G. PY - 2012 DA - 2012// TI - Contrasting acute graft-versus-host disease effects of Tim-3/galectin-9 pathway blockade dependent upon the presence of donor regulatory T cells JO - Blood VL - 120 UR - https://doi.org/10.1182/blood-2011-10-387977 DO - 10.1182/blood-2011-10-387977 ID - Veenstra2012 ER - TY - JOUR AU - Sanchez-Fueyo, A. PY - 2003 DA - 2003// TI - Tim-3 inhibits T helper type 1-mediated auto- and alloimmune responses and promotes immunological tolerance JO - Nat Immunol VL - 4 UR - https://doi.org/10.1038/ni987 DO - 10.1038/ni987 ID - Sanchez-Fueyo2003 ER - TY - JOUR AU - He, W. PY - 2009 DA - 2009// TI - Galectin-9 significantly prolongs the survival of fully mismatched cardiac allografts in mice JO - Transplantation VL - 88 UR - https://doi.org/10.1097/TP.0b013e3181b47f25 DO - 10.1097/TP.0b013e3181b47f25 ID - He2009 ER - TY - JOUR AU - Seki, M. PY - 2008 DA - 2008// TI - Galectin-9 suppresses the generation of Th17, promotes the induction of regulatory T cells, and regulates experimental autoimmune arthritis JO - Clin Immunol VL - 127 UR - https://doi.org/10.1016/j.clim.2008.01.006 DO - 10.1016/j.clim.2008.01.006 ID - Seki2008 ER - TY - JOUR AU - Chou, F. C. PY - 2013 DA - 2013// TI - Overexpression of galectin-9 in islets prolongs grafts survival via downregulation of Th1 responses JO - Cell Transplant VL - 22 UR - https://doi.org/10.3727/096368912X657891 DO - 10.3727/096368912X657891 ID - Chou2013 ER - TY - JOUR AU - Oomizu, S. PY - 2012 DA - 2012// TI - Galectin-9 suppresses Th17 cell development in an IL-2-dependent but Tim-3-independent manner JO - Clin Immunol VL - 143 UR - https://doi.org/10.1016/j.clim.2012.01.004 DO - 10.1016/j.clim.2012.01.004 ID - Oomizu2012 ER - TY - JOUR AU - Boenisch, O. PY - 2010 DA - 2010// TI - TIM-3: a novel regulatory molecule of alloimmune activation JO - J Immunol VL - 185 UR - https://doi.org/10.4049/jimmunol.0903435 DO - 10.4049/jimmunol.0903435 ID - Boenisch2010 ER - TY - JOUR AU - Hastings, W. D. PY - 2009 DA - 2009// TI - TIM-3 is expressed on activated human CD4+ T cells and regulates Th1 and Th17 cytokines JO - Eur J Immunol VL - 39 UR - https://doi.org/10.1002/eji.200939274 DO - 10.1002/eji.200939274 ID - Hastings2009 ER - TY - JOUR AU - Golden-Mason, L. PY - 2009 DA - 2009// TI - Negative immune regulator Tim-3 is overexpressed on T cells in hepatitis C virus infection and its blockade rescues dysfunctional CD4+ and CD8+ T cells JO - J Virol VL - 83 UR - https://doi.org/10.1128/JVI.00639-09 DO - 10.1128/JVI.00639-09 ID - Golden-Mason2009 ER - TY - JOUR AU - Jin, H. T. PY - 2010 DA - 2010// TI - Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection JO - Proc Natl Acad Sci U S A VL - 107 UR - https://doi.org/10.1073/pnas.1009731107 DO - 10.1073/pnas.1009731107 ID - Jin2010 ER - TY - JOUR AU - Yang, Z. Z. PY - 2012 DA - 2012// TI - IL-12 upregulates TIM-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphoma JO - J Clin Invest VL - 122 UR - https://doi.org/10.1172/JCI59806 DO - 10.1172/JCI59806 ID - Yang2012 ER - TY - JOUR AU - Fourcade, J. PY - 2010 DA - 2010// TI - Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients JO - J Exp Med VL - 207 UR - https://doi.org/10.1084/jem.20100637 DO - 10.1084/jem.20100637 ID - Fourcade2010 ER - TY - JOUR AU - Sakuishi, K. PY - 2010 DA - 2010// TI - Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity JO - J Exp Med VL - 207 UR - https://doi.org/10.1084/jem.20100643 DO - 10.1084/jem.20100643 ID - Sakuishi2010 ER - TY - JOUR AU - Zhou, Q. PY - 2011 DA - 2011// TI - Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia JO - Blood VL - 117 UR - https://doi.org/10.1182/blood-2010-10-310425 DO - 10.1182/blood-2010-10-310425 ID - Zhou2011 ER - TY - JOUR AU - Takamura, S. PY - 2010 DA - 2010// TI - Premature terminal exhaustion of Friend virus-specific effector CD8+ T cells by rapid induction of multiple inhibitory receptors JO - J Immunol VL - 184 UR - https://doi.org/10.4049/jimmunol.0903478 DO - 10.4049/jimmunol.0903478 ID - Takamura2010 ER - TY - JOUR AU - Wang, L. PY - 2011 DA - 2011// TI - VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses JO - J Exp Med VL - 208 UR - https://doi.org/10.1084/jem.20100619 DO - 10.1084/jem.20100619 ID - Wang2011 ER - TY - JOUR AU - Flies, D. B. PY - 2011 DA - 2011// TI - Cutting edge: A monoclonal antibody specific for the programmed death-1 homolog prevents graft-versus-host disease in mouse models JO - J Immunol VL - 187 UR - https://doi.org/10.4049/jimmunol.1100660 DO - 10.4049/jimmunol.1100660 ID - Flies2011 ER - TY - JOUR AU - Flies, D. B. PY - 2014 DA - 2014// TI - Coinhibitory receptor PD-1H preferentially suppresses CD4(+) T cell-mediated immunity JO - J Clin Invest VL - 124 UR - https://doi.org/10.1172/JCI74589 DO - 10.1172/JCI74589 ID - Flies2014 ER - TY - JOUR AU - Lines, J. L. PY - 2014 DA - 2014// TI - VISTA is an immune checkpoint molecule for human T cells JO - Cancer Res VL - 74 UR - https://doi.org/10.1158/0008-5472.CAN-13-1504 DO - 10.1158/0008-5472.CAN-13-1504 ID - Lines2014 ER - TY - JOUR AU - Mercier, I. PY - 2014 DA - 2014// TI - VISTA Regulates the Development of Protective Antitumor Immunity JO - Cancer Res VL - 74 UR - https://doi.org/10.1158/0008-5472.CAN-13-1506 DO - 10.1158/0008-5472.CAN-13-1506 ID - Mercier2014 ER - TY - JOUR AU - Wang, L. PY - 2014 DA - 2014// TI - Disruption of the immune-checkpoint VISTA gene imparts a proinflammatory phenotype with predisposition to the development of autoimmunity JO - Proc Natl Acad Sci U S A VL - 111 UR - https://doi.org/10.1073/pnas.1407447111 DO - 10.1073/pnas.1407447111 ID - Wang2014 ER - TY - JOUR AU - Liu, J. PY - 2015 DA - 2015// TI - Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses JO - Proc Natl Acad Sci U S A VL - 112 UR - https://doi.org/10.1073/pnas.1420370112 DO - 10.1073/pnas.1420370112 ID - Liu2015 ER - TY - JOUR AU - Sorensen, M. R. PY - 2010 DA - 2010// TI - Adenoviral vaccination combined with CD40 stimulation and CTLA-4 blockage can lead to complete tumor regression in a murine melanoma model JO - Vaccine VL - 28 UR - https://doi.org/10.1016/j.vaccine.2010.07.066 DO - 10.1016/j.vaccine.2010.07.066 ID - Sorensen2010 ER - TY - JOUR AU - Lines, J. L. PY - 2014 DA - 2014// TI - VISTA is a novel broad-spectrum negative checkpoint regulator for cancer immunotherapy JO - Cancer Immunol Res VL - 2 UR - https://doi.org/10.1158/2326-6066.CIR-14-0072 DO - 10.1158/2326-6066.CIR-14-0072 ID - Lines2014 ER - TY - JOUR AU - Bottino, C. PY - 2003 DA - 2003// TI - Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule JO - J Exp Med VL - 198 UR - https://doi.org/10.1084/jem.20030788 DO - 10.1084/jem.20030788 ID - Bottino2003 ER - TY - JOUR AU - Fuchs, A. PY - 2004 DA - 2004// TI - Cutting edge: CD96 (tactile) promotes NK cell-target cell adhesion by interacting with the poliovirus receptor (CD155) JO - J Immunol VL - 172 UR - https://doi.org/10.4049/jimmunol.172.7.3994 DO - 10.4049/jimmunol.172.7.3994 ID - Fuchs2004 ER - TY - JOUR AU - Chan, C. J. PY - 2014 DA - 2014// TI - The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions JO - Nat Immunol VL - 15 UR - https://doi.org/10.1038/ni.2850 DO - 10.1038/ni.2850 ID - Chan2014 ER - TY - JOUR AU - Blake, S. J. PY - 2016 DA - 2016// TI - Molecular Pathways: Targeting CD96 and TIGIT for Cancer Immunotherapy JO - Clin Cancer Res VL - 22 UR - https://doi.org/10.1158/1078-0432.CCR-16-0933 DO - 10.1158/1078-0432.CCR-16-0933 ID - Blake2016 ER - TY - JOUR AU - Hosen, N. PY - 2007 DA - 2007// TI - CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia JO - Proc Natl Acad Sci U S A VL - 104 UR - https://doi.org/10.1073/pnas.0704271104 DO - 10.1073/pnas.0704271104 ID - Hosen2007 ER - TY - JOUR AU - Kaname, T. PY - 2007 DA - 2007// TI - Mutations in CD96, a member of the immunoglobulin superfamily, cause a form of the C (Opitz trigonocephaly) syndrome JO - Am J Hum Genet VL - 81 UR - https://doi.org/10.1086/522014 DO - 10.1086/522014 ID - Kaname2007 ER - TY - JOUR AU - Gong, J. PY - 2009 DA - 2009// TI - Establishment of an enzyme-linked immunosorbent assay system for determining soluble CD96 and its application in the measurement of sCD96 in patients with viral hepatitis B and hepatic cirrhosis JO - Clin Exp Immunol VL - 155 UR - https://doi.org/10.1111/j.1365-2249.2008.03829.x DO - 10.1111/j.1365-2249.2008.03829.x ID - Gong2009 ER - TY - JOUR AU - Eriksson, E. M. PY - 2012 DA - 2012// TI - Differential expression of CD96 surface molecule represents CD8(+) T cells with dissimilar effector function during HIV-1 infection JO - PLoS One VL - 7 UR - https://doi.org/10.1371/journal.pone.0051696 DO - 10.1371/journal.pone.0051696 ID - Eriksson2012 ER - TY - JOUR AU - He, J. PY - 2015 DA - 2015// TI - Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer JO - Sci Rep VL - 5 UR - https://doi.org/10.1038/srep13110 DO - 10.1038/srep13110 ID - He2015 ER - TY - JOUR AU - Eggermont, A. M. PY - 2015 DA - 2015// TI - Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial JO - Lancet Oncol VL - 16 UR - https://doi.org/10.1016/S1470-2045(15)70122-1 DO - 10.1016/S1470-2045(15)70122-1 ID - Eggermont2015 ER - TY - JOUR AU - Hodi, F. S. PY - 2010 DA - 2010// TI - Improved survival with ipilimumab in patients with metastatic melanoma JO - N Engl J Med VL - 363 UR - https://doi.org/10.1056/NEJMoa1003466 DO - 10.1056/NEJMoa1003466 ID - Hodi2010 ER - TY - JOUR AU - Barker, C. A. PY - 2013 DA - 2013// TI - Concurrent radiotherapy and ipilimumab immunotherapy for patients with melanoma JO - Cancer Immunol Res VL - 1 UR - https://doi.org/10.1158/2326-6066.CIR-13-0082 DO - 10.1158/2326-6066.CIR-13-0082 ID - Barker2013 ER - TY - JOUR AU - Qin, R. PY - 2016 DA - 2016// TI - Safety and Efficacy of Radiation Therapy in Advanced Melanoma Patients Treated With Ipilimumab JO - Int J Radiat Oncol Biol Phys VL - 96 UR - https://doi.org/10.1016/j.ijrobp.2016.04.017 DO - 10.1016/j.ijrobp.2016.04.017 ID - Qin2016 ER - TY - JOUR AU - Hodi, F. S. PY - 2014 DA - 2014// TI - Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial JO - JAMA VL - 312 UR - https://doi.org/10.1001/jama.2014.13943 DO - 10.1001/jama.2014.13943 ID - Hodi2014 ER - TY - JOUR AU - Bashey, A. PY - 2009 DA - 2009// TI - CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation JO - Blood VL - 113 UR - https://doi.org/10.1182/blood-2008-07-168468 DO - 10.1182/blood-2008-07-168468 ID - Bashey2009 ER - TY - JOUR AU - Zimmer, L. PY - 2015 DA - 2015// TI - Phase II DeCOG-study of ipilimumab in pretreated and treatment-naive patients with metastatic uveal melanoma JO - PLoS One VL - 10 UR - https://doi.org/10.1371/journal.pone.0118564 DO - 10.1371/journal.pone.0118564 ID - Zimmer2015 ER - TY - JOUR AU - Ralph, C. PY - 2010 DA - 2010// TI - Modulation of lymphocyte regulation for cancer therapy: a phase II trial of tremelimumab in advanced gastric and esophageal adenocarcinoma JO - Clin Cancer Res VL - 16 UR - https://doi.org/10.1158/1078-0432.CCR-09-2870 DO - 10.1158/1078-0432.CCR-09-2870 ID - Ralph2010 ER - TY - JOUR AU - Antonia, S. PY - 2016 DA - 2016// TI - Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study JO - Lancet Oncol VL - 17 UR - https://doi.org/10.1016/S1470-2045(15)00544-6 DO - 10.1016/S1470-2045(15)00544-6 ID - Antonia2016 ER - TY - JOUR AU - Sangro, B. PY - 2013 DA - 2013// TI - A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C JO - J Hepatol VL - 59 UR - https://doi.org/10.1016/j.jhep.2013.02.022 DO - 10.1016/j.jhep.2013.02.022 ID - Sangro2013 ER - TY - STD TI - Duffy AG, et al. Tremelimumab in Combination with Ablation in Patients with Advanced Hepatocellular Carcinoma. J Hepatol. 2016. doi: 10.1016/j.jhep.2016.10.029. ID - ref180 ER - TY - JOUR AU - Calabro, L. PY - 2013 DA - 2013// TI - Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial JO - Lancet Oncol VL - 14 UR - https://doi.org/10.1016/S1470-2045(13)70381-4 DO - 10.1016/S1470-2045(13)70381-4 ID - Calabro2013 ER - TY - JOUR AU - Guazzelli, A. PY - 2015 DA - 2015// TI - Tremelimumab for the treatment of malignant mesothelioma JO - Expert Opin Biol Ther VL - 15 UR - https://doi.org/10.1517/14712598.2015.1116515 DO - 10.1517/14712598.2015.1116515 ID - Guazzelli2015 ER - TY - JOUR AU - Ribas, A. PY - 2013 DA - 2013// TI - Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma JO - J Clin Oncol VL - 31 UR - https://doi.org/10.1200/JCO.2012.44.6112 DO - 10.1200/JCO.2012.44.6112 ID - Ribas2013 ER - TY - JOUR AU - Tarhini, A. A. PY - 2012 DA - 2012// TI - Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma JO - J Clin Oncol VL - 30 UR - https://doi.org/10.1200/JCO.2011.37.5394 DO - 10.1200/JCO.2011.37.5394 ID - Tarhini2012 ER - TY - JOUR AU - Chung, K. Y. PY - 2010 DA - 2010// TI - Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer JO - J Clin Oncol VL - 28 UR - https://doi.org/10.1200/JCO.2010.28.3994 DO - 10.1200/JCO.2010.28.3994 ID - Chung2010 ER - TY - JOUR AU - Robert, C. PY - 2015 DA - 2015// TI - Nivolumab in previously untreated melanoma without BRAF mutation JO - N Engl J Med VL - 372 UR - https://doi.org/10.1056/NEJMoa1412082 DO - 10.1056/NEJMoa1412082 ID - Robert2015 ER - TY - JOUR AU - Postow, M. A. PY - 2015 DA - 2015// TI - Nivolumab and ipilimumab versus ipilimumab in untreated melanoma JO - N Engl J Med VL - 372 UR - https://doi.org/10.1056/NEJMoa1414428 DO - 10.1056/NEJMoa1414428 ID - Postow2015 ER - TY - JOUR AU - Larkin, J. PY - 2015 DA - 2015// TI - Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma JO - N Engl J Med VL - 373 UR - https://doi.org/10.1056/NEJMoa1504030 DO - 10.1056/NEJMoa1504030 ID - Larkin2015 ER - TY - JOUR AU - Weber, J. S. PY - 2015 DA - 2015// TI - Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial JO - Lancet Oncol VL - 16 UR - https://doi.org/10.1016/S1470-2045(15)70076-8 DO - 10.1016/S1470-2045(15)70076-8 ID - Weber2015 ER - TY - JOUR AU - Gettinger, S. N. PY - 2015 DA - 2015// TI - Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer JO - J Clin Oncol VL - 33 UR - https://doi.org/10.1200/JCO.2014.58.3708 DO - 10.1200/JCO.2014.58.3708 ID - Gettinger2015 ER - TY - JOUR AU - Brahmer, J. PY - 2015 DA - 2015// TI - Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer JO - N Engl J Med VL - 373 UR - https://doi.org/10.1056/NEJMoa1504627 DO - 10.1056/NEJMoa1504627 ID - Brahmer2015 ER - TY - JOUR AU - Borghaei, H. PY - 2015 DA - 2015// TI - Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer JO - N Engl J Med VL - 373 UR - https://doi.org/10.1056/NEJMoa1507643 DO - 10.1056/NEJMoa1507643 ID - Borghaei2015 ER - TY - JOUR AU - Herbst, R. S. PY - 2016 DA - 2016// TI - Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial JO - Lancet VL - 387 UR - https://doi.org/10.1016/S0140-6736(15)01281-7 DO - 10.1016/S0140-6736(15)01281-7 ID - Herbst2016 ER - TY - JOUR AU - Ribas, A. PY - 2016 DA - 2016// TI - Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma JO - JAMA VL - 315 UR - https://doi.org/10.1001/jama.2016.4059 DO - 10.1001/jama.2016.4059 ID - Ribas2016 ER - TY - JOUR AU - Le, D. T. PY - 2015 DA - 2015// TI - PD-1 Blockade in Tumors with Mismatch-Repair Deficiency JO - N Engl J Med VL - 372 UR - https://doi.org/10.1056/NEJMoa1500596 DO - 10.1056/NEJMoa1500596 ID - Le2015 ER - TY - JOUR AU - Rizvi, N. A. PY - 2015 DA - 2015// TI - Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer JO - Science VL - 348 UR - https://doi.org/10.1126/science.aaa1348 DO - 10.1126/science.aaa1348 ID - Rizvi2015 ER - TY - JOUR AU - Roszik, J. PY - 2016 DA - 2016// TI - Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set JO - BMC Med VL - 14 UR - https://doi.org/10.1186/s12916-016-0705-4 DO - 10.1186/s12916-016-0705-4 ID - Roszik2016 ER - TY - JOUR AU - Rebhandl, S. PY - 2015 DA - 2015// TI - AID/APOBEC deaminases and cancer JO - Oncoscience VL - 2 UR - https://doi.org/10.18632/oncoscience.155 DO - 10.18632/oncoscience.155 ID - Rebhandl2015 ER - TY - JOUR AU - Westin, J. R. PY - 2014 DA - 2014// TI - Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial JO - Lancet Oncol VL - 15 UR - https://doi.org/10.1016/S1470-2045(13)70551-5 DO - 10.1016/S1470-2045(13)70551-5 ID - Westin2014 ER - TY - JOUR AU - Armand, P. PY - 2013 DA - 2013// TI - Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial JO - J Clin Oncol VL - 31 UR - https://doi.org/10.1200/JCO.2012.48.3685 DO - 10.1200/JCO.2012.48.3685 ID - Armand2013 ER - TY - JOUR AU - Fehrenbacher, L. PY - 2016 DA - 2016// TI - Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial JO - Lancet VL - 387 UR - https://doi.org/10.1016/S0140-6736(16)00587-0 DO - 10.1016/S0140-6736(16)00587-0 ID - Fehrenbacher2016 ER - TY - JOUR AU - Rosenberg, J. E. PY - 2016 DA - 2016// TI - Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial JO - Lancet VL - 387 UR - https://doi.org/10.1016/S0140-6736(16)00561-4 DO - 10.1016/S0140-6736(16)00561-4 ID - Rosenberg2016 ER - TY - STD TI - Bendell JC. Cobimetinib Plus Atezolizumab Active in Microsatellite Stable mCRC - See more at: http://global.onclive.com/conference-coverage/2016-world-gi/cobimetinib-plus-atezolizumab-active-in-microsatellite-stable-mcrc?p=2#sthash.djKjryZZ.dpuf. 2016 World Congress on GI Cancer 2016. UR - http://global.onclive.com/conference-coverage/2016-world-gi/cobimetinib-plus-atezolizumab-active-in-microsatellite-stable-mcrc?p=2#sthash.djKjryZZ.dpuf ID - ref203 ER - TY - JOUR AU - Rizvi, N. A. PY - 2015 DA - 2015// TI - Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial JO - Lancet Oncol VL - 16 UR - https://doi.org/10.1016/S1470-2045(15)70054-9 DO - 10.1016/S1470-2045(15)70054-9 ID - Rizvi2015 ER - TY - JOUR AU - Yamazaki, N. PY - 2015 DA - 2015// TI - Phase II study of ipilimumab monotherapy in Japanese patients with advanced melanoma JO - Cancer Chemother Pharmacol VL - 76 UR - https://doi.org/10.1007/s00280-015-2873-x DO - 10.1007/s00280-015-2873-x ID - Yamazaki2015 ER - TY - JOUR AU - Ansell, S. M. PY - 2015 DA - 2015// TI - PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma JO - N Engl J Med VL - 372 UR - https://doi.org/10.1056/NEJMoa1411087 DO - 10.1056/NEJMoa1411087 ID - Ansell2015 ER - TY - JOUR AU - Vonderheide, R. H. PY - 2010 DA - 2010// TI - Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cells JO - Clin Cancer Res VL - 16 UR - https://doi.org/10.1158/1078-0432.CCR-10-0505 DO - 10.1158/1078-0432.CCR-10-0505 ID - Vonderheide2010 ER - TY - JOUR AU - McNeel, D. G. PY - 2012 DA - 2012// TI - Phase I trial of tremelimumab in combination with short-term androgen deprivation in patients with PSA-recurrent prostate cancer JO - Cancer Immunol Immunother VL - 61 UR - https://doi.org/10.1007/s00262-011-1193-1 DO - 10.1007/s00262-011-1193-1 ID - McNeel2012 ER - TY - JOUR AU - Wang-Gillam, A. PY - 2013 DA - 2013// TI - A phase I study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinoma JO - Invest New Drugs VL - 31 UR - https://doi.org/10.1007/s10637-012-9866-y DO - 10.1007/s10637-012-9866-y ID - Wang-Gillam2013 ER - TY - JOUR AU - Chen, L. AU - Flies, D. B. PY - 2013 DA - 2013// TI - Molecular mechanisms of T cell co-stimulation and co-inhibition JO - Nat Rev Immunol VL - 13 UR - https://doi.org/10.1038/nri3405 DO - 10.1038/nri3405 ID - Chen2013 ER - TY - STD TI - Thaventhiran T, Sethu S, Yeang HXA, Al-Huseini L, Hamdam J, Sathish JG. T Cell Co-inhibitory Receptors: Functions and Signalling Mechanisms. J Clin Cell Immunol. 2012;S12:004. doi:10.4172/2155-9899.S12-004. ID - ref211 ER - TY - STD TI - Bajor DLM, e.a.,.CT137 – Combination of Agonistic CD40 Monoclonal Antibody CP-870,893 aNM Anti-CTLA-4 Antibody Tremelimumab in Patients with Metastatic Melanoma. Proceedings, Part 2: Clinical Trials aNM Late-Breaking Abstracts. Clinical Trials Plenary Session: Combinations of Therapeutic Agents. AACR. Vol. Part 2. I. Philadelphia, PA: AACR.org; 2015. ID - ref212 ER - TY - STD TI - Zatloukal P, Heo DS, Park K, Kang J, Butts C, Bradford D, Graziano S, Huang B, Healey D. Randomized phase II clinical trial comparing tremelimumab (CP-675,206) with best supportive care (BSC) following first-line platinum-based therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC). J Clin Oncol. 2009;27(15_suppl):8071. ID - ref213 ER - TY - JOUR AU - Calabro, L. PY - 2015 DA - 2015// TI - Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study JO - Lancet Respir Med VL - 3 UR - https://doi.org/10.1016/S2213-2600(15)00092-2 DO - 10.1016/S2213-2600(15)00092-2 ID - Calabro2015 ER - TY - JOUR AU - Hamanishi, J. PY - 2015 DA - 2015// TI - Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer JO - J Clin Oncol VL - 33 UR - https://doi.org/10.1200/JCO.2015.62.3397 DO - 10.1200/JCO.2015.62.3397 ID - Hamanishi2015 ER - TY - JOUR AU - Motzer, R. J. PY - 2015 DA - 2015// TI - Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma JO - N Engl J Med VL - 373 UR - https://doi.org/10.1056/NEJMoa1510665 DO - 10.1056/NEJMoa1510665 ID - Motzer2015 ER - TY - JOUR AU - Garon, E. B. PY - 2015 DA - 2015// TI - Pembrolizumab for the treatment of non-small-cell lung cancer JO - N Engl J Med VL - 372 UR - https://doi.org/10.1056/NEJMoa1501824 DO - 10.1056/NEJMoa1501824 ID - Garon2015 ER - TY - JOUR AU - Nanda, R. PY - 2016 DA - 2016// TI - Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study JO - J Clin Oncol VL - 34 UR - https://doi.org/10.1200/JCO.2015.64.8931 DO - 10.1200/JCO.2015.64.8931 ID - Nanda2016 ER - TY - JOUR AU - Robert, C. PY - 2015 DA - 2015// TI - Pembrolizumab versus Ipilimumab in Advanced Melanoma JO - N Engl J Med VL - 372 UR - https://doi.org/10.1056/NEJMoa1503093 DO - 10.1056/NEJMoa1503093 ID - Robert2015 ER - TY - JOUR AU - Twyman-Saint Victor, C. PY - 2015 DA - 2015// TI - Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer JO - Nature VL - 520 UR - https://doi.org/10.1038/nature14292 DO - 10.1038/nature14292 ID - Twyman-Saint Victor2015 ER - TY - JOUR AU - Horinouchi, H. PY - 2015 DA - 2015// TI - Phase I study of ipilimumab in phased combination with paclitaxel and carboplatin in Japanese patients with non-small-cell lung cancer JO - Invest New Drugs VL - 33 UR - https://doi.org/10.1007/s10637-015-0243-5 DO - 10.1007/s10637-015-0243-5 ID - Horinouchi2015 ER - TY - JOUR AU - Kwon, E. D. PY - 2014 DA - 2014// TI - Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial JO - Lancet Oncol VL - 15 UR - https://doi.org/10.1016/S1470-2045(14)70189-5 DO - 10.1016/S1470-2045(14)70189-5 ID - Kwon2014 ER - TY - JOUR AU - Aglietta, M. PY - 2014 DA - 2014// TI - A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer JO - Ann Oncol VL - 25 UR - https://doi.org/10.1093/annonc/mdu205 DO - 10.1093/annonc/mdu205 ID - Aglietta2014 ER - TY - JOUR AU - Millward, M. PY - 2013 DA - 2013// TI - Phase I study of tremelimumab (CP-675 206) plus PF-3512676 (CPG 7909) in patients with melanoma or advanced solid tumours JO - Br J Cancer VL - 108 UR - https://doi.org/10.1038/bjc.2013.227 DO - 10.1038/bjc.2013.227 ID - Millward2013 ER - TY - JOUR AU - Rini, B. I. PY - 2011 DA - 2011// TI - Phase 1 dose-escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma JO - Cancer VL - 117 UR - https://doi.org/10.1002/cncr.25639 DO - 10.1002/cncr.25639 ID - Rini2011 ER - TY - JOUR AU - Gibney, G. T. PY - 2015 DA - 2015// TI - Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma JO - Clin Cancer Res VL - 21 UR - https://doi.org/10.1158/1078-0432.CCR-14-2468 DO - 10.1158/1078-0432.CCR-14-2468 ID - Gibney2015 ER -